Talking PAH: Novel Therapies for Pulmonary Arterial Hypertension

AMA/ANCC/ACPE Activity Archive
Pulmonary arterial hypertension (PAH) is a debilitating and progressive disease characterized by pulmonary artery vasoconstriction and vascular remodeling leading to elevation of pulmonary arterial pressures and pulmonary vascular resistance. Current PAH-specific therapies have significantly improved the outlook for patients by improving functional capacity, pulmonary hemodynamics and reducing hospitalization. PAH remains an incurable disease necessitating further research and treatment options. This webcast provides an update on novel advances in pharmacological therapy in PAH.
This activity will focus on several important aspects of PAH management including a discussion of clinical trial data on emerging therapeutics for the management of PAH; and a review of strategies to optimize outcomes for patients with PAH.
FACULTY
Mardi Gomberg Maitland, MD, MSc
Director of Pulmonary Hypertension
George Washington University School of Medicine and Health Sciences
Marc Humbert, MD, PhD
Professor of Medicine, University Paris-Saclay
Department of Respiratory Medicine, Hopital Bicetre
Aaron B. Waxman, MD, PhD
Executive Director
Center for Pulmonary Heart Disease
Review the activity at bit.ly/3wtctCs and claim AMA, ANCC or ACPE credit/contact hour after completion of a brief pretest and posttest/evaluation.
This activity is provided in collaboration with Rush University Medical Center and Practice Point Communications.
Supported by an independent educational grant from Acceleron Pharma Inc.